Article
Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics - 15 Aug 2003
Gearry R B, Barclay M L, Burt M J, Collett J A, Chapman B A, Roberts R L, Kennedy M A
Abstract excerpt
BACKGROUND: Azathioprine and mercaptopurine (MP) are well established treatments for inflammatory bowel disease but they have severe adverse effects that prevent their use in some patients. The likelihood and type of adverse effect may relate to thiopurine methyltransferase (TPMT) enzyme activity and genotype. AIM: To compare the TPMT genotype frequencies in patients with inflammatory bowel disease who have had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
